Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 11:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 1,486 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: MR Clear all
Completed No phase listed Observational Accepts healthy volunteers

Use of in Vivo 3T MR to Characterize Carotid Plaque in Patients and Correlate MR Findings With Symptoms

NCT02335567
View directory record Official record
Conditions
Carotid Plaque Hemorrhage Appearance
Interventions
there is no intervention
Other
Lead sponsor
Michigan State University
Other
Eligibility
20 Years to 85 Years
Enrollment
162 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
East Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 16, 2016 · Synced Oct 26, 2026, 11:31 PM EDT
Recruiting Phase 2 Interventional

Mammogram Pretreatment With Ulipristal Acetate

NCT07434128
View directory record Official record
Conditions
Mammography Screening, Breast Density
Interventions
Biospecimen Collection, Magnetic Resonance Imaging, Mammogram, Survey Administration, Ulipristal Acetate
Procedure · Other · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 26, 2026, 11:31 PM EDT
Completed Not applicable Interventional

Neural Mechanisms of Mindfulness-based Cognitive Therapy (MBCT) for PTSD - COVID Related Substudy

NCT04540939
View directory record Official record
Conditions
Trauma
Interventions
Mindfulness-Based Cognitive Therapy, Muscle Relaxation Therapy
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 72 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Ann Arbor, Michigan • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Oct 26, 2026, 11:31 PM EDT
Completed No phase listed Observational Results available

Cerebral Effects of Pegylated Interferon in Hepatitis C Positive Subjects

NCT00136214
View directory record Official record
Conditions
Hepatitis C
Interventions
MR brain and neuropsychiatric tests
Diagnostic Test
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Oct 26, 2026, 11:31 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer

NCT04821284
View directory record Official record
Conditions
Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8, Stage IIB Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Ductal Adenocarcinoma
Interventions
Gemcitabine Hydrochloride, Nab-paclitaxel, Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium, Oxaliplatin, Perflubutane Microbubble, Contrast-Enhanced Ultrasound, Quality-of-Life Assessment, Computed Tomography, Magnetic Resonance Imaging
Drug · Other · Procedure
Lead sponsor
Flemming Forsberg
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 26, 2026, 11:31 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Comparison of Magnetic Resonance Imaging in Persons With Heart Failure to Health, Aged Matched Controls

NCT02572648
View directory record Official record
Conditions
Heart Failure
Interventions
Brain Imaging (Neuroimaging), Cognitive Function Assessment
Other
Lead sponsor
Emory University
Other
Eligibility
40 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 21, 2017 · Synced Oct 26, 2026, 11:31 PM EDT
Completed Not applicable Interventional

Using Virtual Reality (VR) Models for Robotic Prostatectomy

NCT03943368
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ceevra Reveal
Device
Lead sponsor
Ceevra, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
6
States / cities
Los Angeles, California • Orange, California • Jacksonville, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Oct 26, 2026, 11:31 PM EDT
Not listed Phase 2 Interventional

IRAK 4 Inhibitor (PF-06650833) in Hospitalized Patients With COVID-19 Pneumonia and Exuberant Inflammation.

NCT04933799
View directory record Official record
Conditions
COVID-19 Pneumonia
Interventions
PF-06650833, Matching Placebo
Drug
Lead sponsor
Giovanni Franchin, M.D, Ph.D
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Oct 26, 2026, 11:31 PM EDT
Terminated Phase 2 Interventional Results available

Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study

NCT05960578
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8
Interventions
Apalutamide, Biopsy, Biospecimen Collection, Computed Tomography, Golimumab, Magnetic Resonance Imaging, PSMA PET Scan, Bone Scan
Drug · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 26, 2026, 11:31 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional Results available

De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer

NCT03952585
View directory record Official record
Conditions
Basaloid Squamous Cell Carcinoma, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Oropharyngeal Squamous Cell Carcinoma, Papillary Squamous Cell Carcinoma, Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Squamous Cell Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Cisplatin, Computed Tomography, Fludeoxyglucose F-18, Image Guided Radiation Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Drug · Other + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
493
States / cities
Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 348 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 26, 2026, 11:31 PM EDT
Completed No phase listed Observational

Prospective Evaluation of the Incidence of NSF in Patients With Kidney Disease Undergoing MR

NCT01135316
View directory record Official record
Conditions
Nephrogenic Systemic Fibrosis
Interventions
Ablavar
Drug
Lead sponsor
Lantheus Medical Imaging
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
New York, New York • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Oct 26, 2026, 11:31 PM EDT
Completed Phase 1 Interventional

Using Fiducial Markers to Aid in Prostate Cancer Radiation Treatment

NCT00061347
View directory record Official record
Conditions
Prostate Cancer, Cancer
Interventions
Fiducial marker placement
Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 90 Years · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 23, 2018 · Synced Oct 26, 2026, 11:31 PM EDT
Terminated Phase 2 Interventional Results available

Functional Imaging of T-Cell Activation With [18F]F-AraG in Urothelial Carcinoma Patients Receiving Neoadjuvant Therapy or Patients With Cancer Receiving Standard of Care Anti-PD-1/L1

NCT03007719
View directory record Official record
Conditions
Bladder Cancer
Interventions
Fluorine F 18 Ara-G, Positron Emission Tomography, Magnetic Resonance Imaging
Drug · Procedure
Lead sponsor
Lawrence Fong
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Oct 26, 2026, 11:31 PM EDT
Active, not recruiting Not applicable Interventional

Evaluate The Accuracy Of Breast MRI Biopsy In Diagnosing A Complete Tumor Response For Some Women Following Neoadjuvant Chemotherapy For Breast Cancer

NCT03289195
View directory record Official record
Conditions
Breast Cancer
Interventions
MRI Biopsy
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 26, 2026, 11:31 PM EDT
Completed Not applicable Interventional Results available

Artifact-Free High-Resolution Myocardial Perfusion MRI in Subjects With Abnormal Nuclear Myocardial Perfusion Studies

NCT01949844
View directory record Official record
Conditions
Coronary Artery Disease, CAD
Interventions
regadenoson, Optimark®, Myocardial perfusion MRI
Drug · Device
Lead sponsor
Daniel S. Berman
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Oct 26, 2026, 11:31 PM EDT
Terminated Not applicable Interventional Results available

Refinement and Assessment of New MRI Technologies for Cardiovascular Exams Using the Phillips CMR Patch

NCT06331507
View directory record Official record
Conditions
Cardiomyopathies
Interventions
CMR patch
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced Oct 26, 2026, 11:31 PM EDT
Recruiting Phase 2Phase 3 Interventional

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

NCT07001748
View directory record Official record
Conditions
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Peritoneal Carcinomatosis
Interventions
Standard of Care Chemotherapy, Biospecimen Collection, Computed Tomography, Diagnostic Laparoscopy, Intraperitoneal Port Placement, Magnetic Resonance Imaging, Intraperitoneal Paclitaxel
Drug · Procedure
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
78
States / cities
Irvine, California • Los Angeles, California • Orange, California + 64 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 26, 2026, 11:31 PM EDT
Completed Phase 4 Interventional Results available

Methotrexate Withdrawal Study of Tofacitinib Modified Release Formulation in Subjects With Rheumatoid Arthritis

NCT02831855
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
CP-690,550, Methotrexate, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
694 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
59
States / cities
Huntsville, Alabama • Gilbert, Arizona • Peoria, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2019 · Synced Oct 26, 2026, 11:31 PM EDT
Completed Not applicable Interventional

Is Eovist Suitable for Arterial-Phase MR Imaging of Liver

NCT02684526
View directory record Official record
Conditions
Liver Disease
Interventions
Eovist Contrast, Non Eovist Contrast
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
21 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 26, 2026, 11:31 PM EDT
Recruiting Phase 2 Interventional

Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial

NCT06636734
View directory record Official record
Conditions
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Neck Squamous Cell Carcinoma of Unknown Primary, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Nasopharyngeal Squamous Cell Carcinoma, Metastatic Oral Cavity Squamous Cell Carcinoma, Metastatic Oropharyngeal Squamous Cell Carcinoma, Metastatic Paranasal Sinus Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Nasopharyngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Recurrent Paranasal Sinus Squamous Cell Carcinoma, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Sinonasal Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Lovastatin, Magnetic Resonance Imaging, Pembrolizumab, Positron Emission Tomography
Procedure · Drug · Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 26, 2026, 11:31 PM EDT
Completed Early Phase 1 Interventional

Brain Amyloid- Retention During Wakefulness and Following Emergence From Sleep in Healthy People

NCT02669225
View directory record Official record
Conditions
Normal Physiology
Interventions
[18F]florbetaben
Other
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years to 40 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 26, 2026, 11:31 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Hp129 Xenon Imaging and BOS in Lung Transplantation

NCT03603899
View directory record Official record
Conditions
Bronchiolitis Obliterans
Interventions
Hp 129Xenon
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 26, 2026, 11:31 PM EDT
Recruiting Phase 3 Interventional

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

NCT06589804
View directory record Official record
Conditions
Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Oral Cavity Squamous Cell Carcinoma, Metastatic Oropharyngeal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Refractory Head and Neck Squamous Cell Carcinoma, Refractory Hypopharyngeal Squamous Cell Carcinoma, Refractory Laryngeal Squamous Cell Carcinoma, Refractory Oral Cavity Squamous Cell Carcinoma, Refractory Oropharyngeal Squamous Cell Carcinoma, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions
Biospecimen Collection, Cetuximab, Computed Tomography, Magnetic Resonance Imaging, Pembrolizumab, Positron Emission Tomography
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
202
States / cities
Little Rock, Arkansas • Marysville, California • Palo Alto, California + 162 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 26, 2026, 11:31 PM EDT
Terminated Not applicable Interventional

Image Guided Therapy in the Treatment of Gliomas

NCT01263821
View directory record Official record
Conditions
Glioma
Interventions
Diffusion-weighted magnetic resonance imaging, Perfusion-weighted magnetic resonance imaging, Functional magnetic resonance imaging, Magnetic resonance spectroscopic imaging, Therapeutic conventional surgery, Quality-of-life assessment, Radiation therapy treatment planning/simulation, Intensity-modulated radiation therapy, Questionnaire administration
Procedure · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
7 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 4, 2017 · Synced Oct 26, 2026, 11:31 PM EDT